HomeIndustriesHealthcareOverlooked Stock: PTGX

Overlooked Stock: PTGX

Protagonist Therapeutics (PTGX) rallied 45% after its latest drug trial to treat people with active ulcerative colitis saw success. George Tsilis says there's more positive catalysts behind the stock, particularly its cash pile.

Market On Close

10 Mar 2025

SHARE

ON AIR
12:00 pm
Next Gen Investing
12:00 am
The Wrap
REPLAY
12:30 am
Market On Close
REPLAY
education
2:00 am
Your First Trade
REPLAY
education
2:30 am
Your First Trade
REPLAY
3:00 am
Fast Market
REPLAY
4:00 am
Next Gen Investing
REPLAY
5:00 am
Market Overtime
REPLAY
5:30 am
The Wrap
REPLAY
7:00 am
Morning Movers
8:00 am
Opening Bell With Nicole Petallides
9:00 am
Morning Trade Live
10:00 am
Trading 360
11:00 am
Fast Market
ON AIR
12:00 pm
Next Gen Investing
1:00 pm
The Watch List
2:00 pm
Market On Close
3:30 pm
Market Overtime
REPLAY
4:00 pm
Fast Market
REPLAY
5:00 pm
Next Gen Investing
REPLAY
6:00 pm
The Wrap
REPLAY
education
7:30 pm
Schwab 2026 Outlook
REPLAY
8:30 pm
Market On Close
REPLAY
education
10:00 pm
Schwab 2026 Outlook
REPLAY
11:00 pm
The Wrap
REPLAY

Schwab Network's Newsletters

Daily insights for every investor